[Experimental studies on the antitumor effect of oral antitumor agents on gynecological malignant tumors]

Insights

Oral antitumor agents like tegafur (T) and UFT showed mild effectiveness against small endometrial tumors but significantly reduced recurrence rates in mice. These agents are promising for preventing tumor recurrence in gynecological cancers.

Area of Science:

  • Gynecological Oncology
  • Pharmacology
  • Cancer Research

Context:

  • Nude mice models are utilized to study human endometrial carcinoma.
  • Oral antitumor agents, including tegafur (T) and UFT, are investigated for their efficacy.
  • Long-term administration protocols are employed to assess treatment effects.

Purpose:

  • To evaluate the antitumor effects of oral agents tegafur (T) and UFT on gynecological malignancies.
  • To assess the impact of these agents on tumor growth inhibition, implantation, and recurrence.
  • To determine the potential of oral antitumor agents in maintenance therapy for endometrial cancer.

Summary:

  • Tegafur (T) and UFT demonstrated mild inhibition rates (60.0% and 71.0%, respectively) on small tumors (2-3 mm) but lacked efficacy against larger tumors.
  • UFT showed a slight reduction in tumor implantation rates (70.0%) compared to the control (90.0%).
  • Both T and UFT significantly reduced tumor recurrence rates (30.0%) compared to the control group (70.0%, p < 0.05).

Impact:

  • Oral antitumor agents may be effective in preventing recurrence of gynecological cancers.
  • Maintenance therapy with oral agents shows promise for microscopic disease, particularly in preventing tumor recurrence.
  • Findings suggest a role for oral agents in managing microscopic endometrial carcinoma, focusing on recurrence prevention.